Frequency Of Stroke Acquired Pneumonia in Patients Admitted in Intensive Care Unit with Stroke: Stroke Acquired Pneumonia in ICU Patients

Kashif  Aziz Ahmad; Sidra  Anwar; Tayyaba  Nazir

doi:10.54393/pbmj.v5i4.386

Authors

Kashif Aziz Ahmad Unit-3, Lahore General Hospital / PGMI / AMC
Sidra Anwar Department of Biochemistry, Independent Medical College, Faisalabad
Tayyaba Nazir Tehsil Headquarters Hospital Murree

DOI:

https://doi.org/10.54393/pbmj.v5i4.386

Keywords:

Pneumonia, Stroke, Smoking, Patients, ICU

Abstract

Stroke is a highly morbid entity, and it can be fatal directly due to neurological damage and affecting the respiratory system or can add to overall morbidity and mortality due to its associated complications like stroke-associated pneumonia (SAP). Objective: To investigate the prevalence of stroke-associated pneumonia in ICU patients. Methods: A descriptive case series was conducted at Faisalabad Medical University from October 2020 to April 2021. In this study, the cases of either gender suffering from stroke within 12 hours were included. SAP was labelled on the basis of fever, cough, and non-homogenous opacities on chest X-ray. Results: In the present study, 160 cases of stroke were included, and out of these 82 (51.25%) were males and 78 (48.75%) females. The mean age of the subjects was 54.24±7.15 years and the mean duration of stroke was 7.05±2.54 hours. There were 35 (21.88%) cases that had DM, 28 (17.50%) had HTN and 30 (18.75%) of cases had a history of smoking. In 20 (12.50%) of the patients, SAP was discovered. With a p= 0.34, SAP was found in 12 (15.38%) female patients compared to 8 (9.75%) male cases. With a p= 0.15, SAP was more common in instances with DM, where it was detected in 7 (20%) of the cases compared to 13 (10.4%) in cases without DM. SAP was found in 5 (17.85%) instances of HTN and 4 (13.33%) cases of smoking history, with p values of 0.35 and 1.0, respectively. SAP was found in 15 (14.42%) patients with a stroke length of 6-12 hours, compared to 5 (8.92%) instances with a stroke duration shorter than this, with a p= 0.45. Conclusions: Stroke acquired pneumonia is not uncommon and is seen in more than 1 out of every 10 cases and it is more seen in females and those with a history of DM, HTN, and duration of stroke is 6 to 12 hours, though none of these variables was found statistically significant.

References

Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE and Adams RJ et al. Medical and neurological complications of ischemic stroke: experience from the RANTTAS trial. RANTTAS Investigators. Stroke. 1998;29(2):447-53. doi: 10.1161/01.str.29.2.447.

Ingeman A, Andersen G, Hundborg HH, Svendsen ML and Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011;42(11):3214-8. doi: 10.1161/STROKEAHA.110.610881.

Kim BR, Lee J, Sohn MK, Kim DY, Lee SG and Shin YI et al. Risk Factors and Functional Impact of Medical Complications in Stroke. Ann Rehabil Med. 2017;41(5):753-760. doi: 10.5535/arm.2017.41.5.753.

Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H and Tilston J et al. Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke. 2007;38(8):2284-91. doi: 10.1161/STROKEAHA.106.478156.

Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N and Feng W et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712-8. doi: 10.1002/ana.24262.

Anand N and Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med. 2009;30(1):3-9. doi: 10.1055/s-0028-1119803.

El-Solh AA, Niederman MS and Drinka P. Nursing home-acquired pneumonia: a review of risk factors and therapeutic approaches. Curr Med Res Opin. 2010;26(12):2707-14. doi: 10.1185/03007995.2010.530154.

Kuti JL, Shore E, Palter M and Nicolau DP. Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Semin Respir Crit Care Med. 2009;30(1):102-15. doi: 10.1055/s-0028-1119814.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA and Palmer LB et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. doi: 10.1093/cid/ciw353.

Chalmers JD, Rother C, Salih W and Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):330-9. doi: 10.1093/cid/cit734.

Kung HC, Hoyert DL, Xu J and Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008;56(10):1-120.

Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C and Gabarrús A et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011;66(4):340-6. doi: 10.1136/thx.2010.143982.

Fang WF, Yang KY, Wu CL, Yu CJ, Chen CW and Tu CY et al. Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia. Crit Care. 2011;15(1):R32. doi: 10.1186/cc9979.

Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N and Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-82. doi: 10.1136/thorax.58.5.377.

Sligl WI, Majumdar SR and Marrie TJ. Triaging severe pneumonia: what is the "score" on prediction rules?. Crit Care Med. 2009;37(12):3166-8. doi: 10.1097/CCM.0b013e3181b3a99d.

Phua J, See KC, Chan YH, Widjaja LS, Aung NW and Ngerng WJ et al. Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia. Thorax. 2009;64(7):598-603. doi: 10.1136/thx.2009.113795.

Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G and Rivers E et al. Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study. Crit Care. 2011;15(2):R88. doi: 10.1186/cc10087.

El-Solh AA, Alhajhusain A, Abou Jaoude P and Drinka P. Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest. 2010;138(6):1371-6. doi: 10.1378/chest.10-0494.

España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M and Ortega M et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249-56. doi: 10.1164/rccm.200602-177OC.

Rello J, Rodriguez A, Lisboa T, Gallego M, Lujan M and Wunderink R. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Crit Care Med. 2009;37(2):456-62. doi: 10.1097/CCM.0b013e318194b021.

Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ and Stirling R et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375-84. doi: 10.1086/589754.

Light RW. Clinical practice. Pleural effusion. N Engl J Med. 2002;346(25):1971-7. doi: 10.1056/NEJMcp010731.

Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S and Barer MR et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410-1418. doi: 10.1378/chest.10-1747.